
Guillaume Penaranda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5966163/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Semen May Harbor HIV Despite Effective HAART: Another Piece in the Puzzle. PLoS ONE, 2010, 5, e10569.	2.5	43
2	Sorafenib: Experience and Better ManageÂment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer, 2019, 8, 457-467.	7.7	42
3	Prognosis of advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2016, 28, 433-440.	1.6	38
4	Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ® HPV assay. Journal of Clinical Virology, 2010, 47, 177-181.	3.1	36
5	Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay. Journal of Clinical Virology, 2010, 47, 38-42.	3.1	26
6	Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World Journal of Gastroenterology, 2017, 23, 2545.	3.3	21
7	Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. Journal of Clinical Virology, 2010, 48, 246-250.	3.1	20
8	Medically assisted procreation and transmission of hepatitis C virus: absence of HCV RNA in purified sperm fraction in HIV co-infected patients. Aids, 2006, 20, 241-246.	2.2	17
9	NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. European Journal of Gastroenterology and Hepatology, 2017, 29, 706-715.	1.6	15
10	High Prevalence of Asymptomatic Sexually Transmitted Infections among Men Who Have Sex with Men. Journal of Clinical Medicine, 2014, 3, 1386-1391.	2.4	13
11	Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears reffered to colposcopy. Cancer Biomarkers, 2011, 7, 133-139.	1.7	11
12	Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. Therapeutics and Clinical Risk Management, 2021, Volume 17, 669-677.	2.0	10
13	HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. Archives of Virology, 2013, 158, 1143-1149.	2.1	9
14	Peripheral nerve involvement in Fabry's disease: Which investigations? A case series and review of the literature. Revue Neurologique, 2017, 173, 650-657.	1.5	8
15	Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results. PLoS ONE, 2021, 16, e0254939.	2.5	7
16	An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients. PLoS ONE, 2021, 16, e0257817.	2.5	7
17	Acceptability and efficacy of vaginal self-sampling for genital infection and bacterial vaginosis: A cross-sectional study. PLoS ONE, 2021, 16, e0260021.	2.5	7
18	Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, e986-e991.	1.6	6

Guillaume Penaranda

#	Article	lF	CITATIONS
19	Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays. BMC Infectious Diseases, 2013, 13, 499.	2.9	5
20	Quantification of HPV16 E6/E7 mRNA Spliced Isoforms Viral Load as a Novel Diagnostic Tool for Improving Cervical Cancer Screening. Journal of Clinical Medicine, 2018, 7, 530.	2.4	4
21	Usefulness of the MESH score in a European hepatocellular carcinoma cohort. World Journal of Hepatology, 2017, 9, 711.	2.0	4
22	A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France. Journal of Virus Eradication, 2022, 8, 100065.	0.5	3
23	Intermediate stage treatment: Is <scp>TACE</scp> enough?. Liver International, 2018, 38, 187-187.	3.9	1
24	Prognostication of HCC under sorafenib: Is it always possible?. Liver International, 2020, 40, 1241-1243.	3.9	1
25	Prediction of benefit after transarterial chemoembolization (<scp>TACE</scp>): Subclassifications or scoring systems?. Liver International, 2018, 38, 184-184.	3.9	0
26	ALBIâ€based BCLC nomogram: A new or an additional prognostic tool?. Liver International, 2020, 40, 1785-1786.	3.9	0